天健审〔2025〕7299 号 浙江司太立制药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了浙江司太立制药股份有限公司（以下简称司太立公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是司太 立公司董事会的责任。 二、注册会计师的责任 目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 四、财务报告内部控制审计意见 我们认为，司太立公司于 2024 年 12 月 31 日按照《企业内部控制基本规范》 第 1 页 共 2 页 和相关规定在所有重大方面保持了有效的财务报告内部控制。 天健会计师事务所（特殊普通合伙） 中国注册会计师： 中国·杭州 中国注册会计师： 二〇二五年四月二十九日 第 2 页 共 2 页 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部 ...

目 录 一、关于营业收入扣除情况的专项核查意见………………………第 1—2 页 二、2024 年度营业收入扣除情况表…………………………………第 3—5 页 关于营业收入扣除情况的专项核查意见 天健审〔2025〕7300 号 浙江司太立制药股份有限公司全体股东： 我们接受委托，审计了浙江司太立制药股份有限公司（以下简称司太立公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们核查了后 附的司太立公司管理层编制的《2024 年度营业收入扣除情况表》（以下简称扣 除情况表）。 一、对报告使用者和使用目的的限定 本报告仅供司太立公司年度报告披露时使用，不得用作任何其他目的。我们 同意将本报告作为司太立公司年度报告的必备文件，随同其他文件一起报送并对 外披露。 司太立公司管理层的责任是提供真实、合法、完整的相关资料，按照《上海 证券交易所上市公司自律监管指南第 2 号——业务办理（2024 年 5 月修订）》 （上证函〔2024〕1 ...

关于浙江司太立制药股份有限公司 2024 年度持续督导年度报告书 国泰海通证券股份有限公司 | 保荐机构名称 | 国泰海通证券股份有限公司 | | --- | --- | | 保荐代表人 | 戴嘉鑫、何欢 | 根据《证券法》、《证券发行上市保荐业务管理办法》、《上海证券交易所股票 上市规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等有关法律法规的规定，国泰海通证券股份有限公司（以下简称"国泰海通"） 作为浙江司太立制药股份有限公司（以下简称"司太立"、"发行人"、"公司"） 向特定对象发行股票项目的保荐机构，对司太立进行持续督导，并出具本持续督 导年度报告书： 1 序号 工作内容 实施情况 1 建立健全并有效执行持续督导工作制 度，并针对具体的持续督导工作制定相 应的工作计划 已建立健全并有效执行持续督导制度， 已根据司太立的具体情况制定了相应的 工作计划。 2 根据中国证监会相关规定，在持续督导 工作开始前，与上市公司或相关当事人 签署持续督导协议，明确双方在持续督 导期间的权利义务，并报上海证券交易 所备案 已与司太立签订保荐协议，相关协议已 明确了双方在持续督导期间的权利义 务 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,350,224,699.38, representing a 7.02% increase compared to ¥2,195,986,154.85 in 2023[26] - The net profit attributable to shareholders of the listed company was -¥49,098,979.53, a decrease of 211.00% from ¥44,232,089.55 in the previous year[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥54,129,914.26, down 251.56% from ¥35,714,402.86 in 2023[26] - The net cash flow from operating activities increased significantly to ¥193,502,193.81, a 334.33% rise from ¥44,552,117.23 in the previous year[26] - The total assets of the company at the end of 2024 were ¥6,045,615,210.30, reflecting a 9.59% increase from ¥5,516,420,403.90 at the end of 2023[26] - The net assets attributable to shareholders of the listed company increased to ¥2,628,155,919.06, a 49.96% increase from ¥1,752,604,843.99 in 2023[26] - The basic earnings per share decreased to -0.12 yuan, down 192.31% from the previous year[28] - The weighted average return on equity fell to -2.16%, a decrease of 4.69 percentage points year-on-year[28] Business Operations - The company continued to expand its formulation business, with the fifth batch of centralized procurement products, iodinated contrast agent, progressing well, having completed bidding in 28 provinces by February 2025[40] - The company is focusing on the integration of intermediates, APIs, and formulations while enhancing its international sales layout[40] - The company's domestic formulation business achieved sales revenue of CNY 558 million, a year-on-year increase of 13.75%[41] - International sales of contrast agent raw materials grew rapidly, with a year-on-year increase of 21%[41] - The company's formulation business in Ireland reported sales revenue of CNY 86.203 million, a year-on-year increase of 60%[41] - The company aims to achieve over 40% of its revenue from overseas business in 2024, with end customers across more than 30 countries on five continents[41] Research and Development - R&D expenses totaled ¥140,672,339.26, representing 6.07% of total revenue, with capitalized R&D accounting for 1.45%[70] - The company employed 390 R&D personnel, representing 22% of the total workforce[71] - The company has established multiple R&D bases across Zhejiang, Jiangxi, and Shanghai, equipped with modern laboratories for various research purposes[89] - The company is actively involved in the development of non-ionic iodine contrast agents and gadolinium-based agents[89] - The company achieved a research and development investment of 12,752.69 million RMB for API, representing 5.43% of operating revenue, with a year-on-year increase of 17.72%[103] Environmental Responsibility - The company invested 11,202.68 million CNY in environmental protection during the reporting period[163] - The company achieved a total wastewater discharge of 534,235 tons in 2024, with COD emissions of 170.32 tons and ammonia nitrogen emissions of 3.48 tons[164] - The company has committed to reducing carbon emissions through advanced production processes and the establishment of a photovoltaic power station[185] - The company has established a comprehensive self-monitoring plan for environmental compliance, which is publicly available on the Zhejiang Province self-monitoring information platform[181] - The company has improved its ability to treat high-concentration COD and high-salinity wastewater through technological upgrades[183] Corporate Governance - The company held three shareholder meetings during the reporting period, all in compliance with relevant laws and regulations[124] - The company has independent directors serving on multiple boards, enhancing governance and oversight[129] - The remuneration decision process for directors and senior management is governed by the company's compensation management policy[130] - The company has implemented a performance evaluation system to determine actual remuneration for its directors and senior management[130] - The company has not faced significant changes in competition from controlling shareholders or related parties[124] Future Outlook - The company provided guidance for 2024, expecting revenue to grow by 12% to approximately $1.68 billion[136] - New product launches are anticipated to contribute an additional $200 million in revenue in 2024[137] - The company plans to ensure the timely completion of the project for producing 1,550 tons of non-ionic CT contrast agent raw materials, which will enhance existing production capacity and introduce new products[116] - The company is focused on advancing the registration and certification of key products, including iodinated contrast agents and MRI contrast agents, in 2025[115] - The company plans to enhance its marketing strategy, increasing the budget by 20% to drive user engagement and brand awareness[191]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 685,895,638.22, representing a 6.79% increase compared to CNY 642,300,553.98 in the same period last year[4] - Net profit attributable to shareholders was CNY 14,344,260.54, up 16.79% from CNY 12,282,528.03 year-on-year[4] - Basic earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 in the previous year[5] - Total operating revenue for Q1 2025 reached ¥685,895,638.22, an increase of 6.5% compared to ¥642,300,553.98 in Q1 2024[18] - Net profit for Q1 2025 was ¥14,267,477.92, compared to ¥12,561,260.78 in Q1 2024, representing a growth of 13.6%[19] - The company reported a total comprehensive income of ¥12,614,910.04 for Q1 2025, compared to ¥10,627,895.82 in Q1 2024, reflecting an increase of 18.7%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,228,342,333.94, a 3.02% increase from CNY 6,045,615,210.30 at the end of the previous year[5] - The total assets of the company as of March 31, 2025, amounted to RMB 6,228,342,333.94, an increase from RMB 6,045,615,210.30 on December 31, 2024[15] - Current assets totaled RMB 2,306,341,316.18, compared to RMB 2,230,650,974.85 at the end of 2024, reflecting a growth of approximately 3.4%[14] - The company's total liabilities reached RMB 3,579,225,401.94, up from RMB 3,411,168,190.27, marking an increase of around 4.9%[15] - The total liabilities increased to ¥3,579,225,401.94 from ¥3,411,168,190.27, marking a rise of 4.9%[16] Cash Flow - Cash flow from operating activities decreased by 19.33% to CNY 74,292,103.19 from CNY 92,090,350.43 in the same period last year[4] - The company reported a net cash flow from operating activities of ¥74,292,103.19 for Q1 2025, down from ¥92,090,350.43 in Q1 2024[23] - The company reported a decrease in cash and cash equivalents to RMB 411,420,643.16 from RMB 603,354,765.34, a decline of approximately 31.8%[13] - Cash used for debt repayment amounted to $337.95 million, an increase from $209.73 million in the previous period[24] - Total cash outflow from financing activities was $784.19 million, compared to $533.52 million last year, indicating a significant increase[24] - Net cash flow from financing activities was negative at -$113.99 million, a decline from a positive $14.63 million in the previous period[24] - The net increase in cash and cash equivalents was -$117.21 million, contrasting with a positive increase of $9.21 million last year[24] - The ending balance of cash and cash equivalents was $327.05 million, down from $462.37 million at the end of the previous period[24] Accounts Receivable and Inventory - The company experienced a 48.49% increase in accounts receivable, attributed to revenue growth during the period[7] - Accounts receivable increased significantly to RMB 453,457,783.68 from RMB 305,386,330.92, representing a growth of about 48.5%[14] - Inventory stood at RMB 1,087,742,948.79, slightly down from RMB 1,105,101,273.71, indicating a decrease of approximately 1.6%[14] Research and Development - Research and development expenses decreased by 40.40%, reflecting reduced investment in the research phase[8] - Research and development expenses decreased to ¥19,146,421.88 in Q1 2025 from ¥32,124,934.95 in Q1 2024, a reduction of 40.5%[19] Equity and Return on Equity - The weighted average return on equity decreased to 0.54%, down from 0.70% in the previous year[5] - The total equity of the company as of March 31, 2025, was RMB 2,649,116,932.00, up from RMB 2,634,446,019.73, indicating a slight increase of about 0.6%[15] - The total equity attributable to shareholders rose to ¥2,642,902,613.65 from ¥2,628,155,919.06, an increase of 0.6%[16] Borrowings - Short-term borrowings rose to RMB 1,500,400,259.31 from RMB 1,440,594,009.14, reflecting an increase of about 4.2%[15] - Long-term borrowings increased to RMB 628,266,919.15 from RMB 537,284,899.80, representing a growth of about 16.9%[15]

司太立（603520）公告，2025年第一季度营收为6.86亿元，同比增长6.79%；净利润为1434.43万元，同 比增长16.79%。 ...

证券代码：603520 证券简称：司太立 公告编号：2025-007 浙江司太立制药股份有限公司 2024年年度业绩预告更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 （一）业绩预告期间 2024年1月1日至2024年12月31日 （二）前次业绩预告情况 公司于2025年1月17日披露了公司《2024年年度业绩预告》（公告编号：2025-001）。前次业绩预告具 体内容如下： 经财务部门初步测算，预计2024年全年实现归属于母公司所有者的净利润-3,100万元到-2,500万元，与 上年同期相比，将出现亏损。 预计2024年年度实现归属于母公司所有者的扣除非经常性损益后的净利润-3,900万元到-3,300万元。 （三）更正后的业绩预告情况 重要内容提示： ● 本期业绩预告适用于净利润为负值的情形。 ● 业绩预告更正后：浙江司太立制药股份有限公司（以下简称"公司"）预计2024年全年实现归属于母公 司所有者的净利润-4,910万元，实现归属于母公司所有者的扣除非经常性损益的净利润-5,413万元。 一、本期业绩预告情 ...

Financial Performance - The company expects a net profit attributable to shareholders of -49.10 million yuan for the year 2024, indicating a loss compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be -54.13 million yuan for 2024[5] - In the previous year, the total profit was 45.35 million yuan, with a net profit attributable to shareholders of 44.23 million yuan[6] Asset Management - The company plans to increase asset impairment losses by approximately 12.78 million yuan due to re-evaluation of idle equipment and inventory[8] - An additional depreciation expense of about 2.10 million yuan has been recognized based on fixed asset assessments[9] - The company has acknowledged a cost of approximately 1.75 million yuan related to post-period settlements for the 2024 fiscal year[9] Communication and Forecasting - The board has expressed sincere apologies for the discrepancies in the earnings forecast and is committed to improving communication with auditors[12] - The company has not identified any other significant uncertainties affecting the accuracy of the earnings forecast[11] - The financial data provided is preliminary and will be finalized in the audited annual report for 2024[10] - The company emphasizes the importance of cautious principles in financial forecasting to enhance accuracy[12]

2024 年年度业绩预告更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 证券代码：603520 证券简称：司太立 公告编号：2025-007 浙江司太立制药股份有限公司 2024 年 1 月 1 日至 2024 年 12 月 31 日 （二）前次业绩预告情况 公司于 2025 年 1 月 17 日披露了公司《2024 年年度业绩预告》（公告编号： 2025-001）。前次业绩预告具体内容如下： 经财务部门初步测算，预计 2024 年全年实现归属于母公司所有者的净利润 -3,100 万元到-2,500 万元，与上年同期相比，将出现亏损。 预计 2024 年年度实现归属于母公司所有者的扣除非经常性损益后的净利润 -3,900 万元到-3,300 万元。 1 本期业绩预告适用于净利润为负值的情形。 业绩预告更正后：浙江司太立制药股份有限公司（以下简称"公司"）预 计 2024 年全年实现归属于母公司所有者的净利润-4,910 万元，实现归 属于母公司所有者的扣除非经 ...

重要内容提示： 截至本公告披露日，倪莲慧持有浙江司太立制药股份有限公司（以下简 称"公司"）股份数量 22,000,000 股，占公司总股本比例为 5.0181%。其中处于 冻结状态的股份数量 1,500,000 股，占其所持公司股份比例 6.8182%，占公司总 股本比例 0.3421%。 本次倪莲慧拟被司法拍卖的股份数量为 1,500,000 股，占其所持公司股份 比例 6.8182%，占公司总股本比例 0.3421%。 本次拍卖事项尚在公示阶段，拍卖结果存在不确定性，公司会持续关注 该事项的进展情况，并按法律法规的相关规定及时履行信息披露义务，敬请广大 投资者注意投资风险。 倪莲慧不属于公司的控股股东、实际控制人，该事项不会导致公司控制 权发生变更，亦不会对公司日常经营与管理造成影响。 证券代码：603520 证券简称：司太立 公告编号：2025-006 浙江司太立制药股份有限公司 关于持股 5%以上股东部分股份将被司法拍卖 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司近日收到倪莲慧的通知，其收到山 ...